Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341.

被引：0
|
作者：
Hideshima, T [1 ]
Mitsiades, C [1 ]
Akiyama, M [1 ]
Hayashi, T [1 ]
Chauhan, D [1 ]
Richardson, PG [1 ]
Schlossman, RL [1 ]
Podar, K [1 ]
Munshi, NC [1 ]
Mitsiades, N [1 ]
Anderson, KC [1 ]
机构：
[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3215
引用
收藏
页码：814A / 814A
页数：1
相关论文
共 50 条
  • [31] MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity
    Saha, Manujendra N.
    Jiang, Hua
    Jayakar, Jennifer
    Reece, Donna
    Branch, Donald R.
    Chang, Hong
    CANCER BIOLOGY & THERAPY, 2010, 9 (11) : 936 - 944
  • [32] Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839
    Sharma, Deepika
    Ravillah, Durgadevi
    Ray, Arghya
    Song, Yan
    Munshi, Nikhil C.
    Richardson, Paul G.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2014, 124 (21)
  • [33] The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    Ma, MH
    Yang, HH
    Parker, K
    Manyak, S
    Friedman, JM
    Altamirano, C
    Wu, ZQ
    Borad, MJ
    Frantzen, M
    Roussos, E
    Neeser, J
    Mikail, A
    Adams, J
    Sjak-Shie, N
    Vescio, RA
    Berenson, JR
    CLINICAL CANCER RESEARCH, 2003, 9 (03) : 1136 - 1144
  • [34] Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model.
    LeBlanc, R
    Catley, L
    Hideshima, T
    Pien, CS
    Elliott, PJ
    Anderson, KC
    BLOOD, 2001, 98 (11) : 774A - 774A
  • [35] The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation
    Bardag-Gorce, F
    Riley, NE
    Nan, L
    Montgomery, RO
    Li, J
    French, BA
    Lue, YH
    French, SW
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2004, 76 (01) : 9 - 16
  • [36] Anti-myeloma activity of pamidronate in vivo
    Dhodapkar, MV
    Singh, J
    Mehta, J
    Fassas, A
    Desikan, KR
    Perlman, M
    Munshi, NC
    Barlogie, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (02) : 530 - 532
  • [37] The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Mitsiades, N
    Mitsiades, CS
    Richardson, PG
    Poulaki, V
    Tai, YT
    Chauhan, D
    Fanourakis, G
    Gu, XS
    Bailey, C
    Joseph, M
    Libermann, TA
    Schlossman, R
    Munshi, NC
    Hideshima, T
    Anderson, KC
    BLOOD, 2003, 101 (06) : 2377 - 2380
  • [38] In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
    Negri, Joseph M.
    McMillin, Douglas W.
    Delmore, Jake
    Mitsiades, Nicholas
    Hayden, Patrick
    Klippel, Steffen
    Hideshima, Teru
    Chauhan, Dharminder
    Munshi, Nikhil C.
    Buser, Carolyn A.
    Pollard, John
    Richardson, Paul G.
    Anderson, Kenneth C.
    Mitsiades, Constantine S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (05) : 672 - 676
  • [39] Development of a novel pharmacological Hsp70 inhibitor with anti-myeloma activity
    Chatterjee, M.
    Sotriffer, C. A.
    Mueller, E.
    Peinz, U.
    Zilian, D.
    Hartung, A.
    Holzgrabe, U.
    Einsele, H.
    Bargou, R. C.
    ONKOLOGIE, 2012, 35 : 159 - 159
  • [40] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
12345